Jennifer A. Woyach, MD
Long-term data with the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL), explained Jennifer Woyach, MD.
“This regimen appears to be very safe, very tolerable over long periods of time, and very effective,” said Woyach, an associate professor at The Ohio State University Comprehensive Cancer Center.
At the 2019 ASCO Annual Meeting, Woyach presented 3-year follow-up data on the combination of acalabrutinib and obinutuzumab in both patients with treatment-naïve and relapsed/refractory CLL.
... to read the full story